NervGen Pharma Corp.

NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapies designed to support nervous system repair after injury or disease. The company’s lead program, NVG-291, is being studied in spinal cord injury and other neurologic conditions, while its pipeline also includes additional candidates in preclinical development. NervGen’s work centers on addressing biological barriers that limit neural recovery, with applications across neurotrauma and neurodegenerative disease areas. The company’s research and development efforts are aimed at advancing treatments for conditions such as spinal cord injury, stroke, multiple sclerosis, and amyotrophic lateral sclerosis, positioning NervGen Pharma Corp. as a specialized participant in the emerging neuroreparative medicine segment of biotechnology.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Adam H. Rogers M.D.

Employees

9

Headquarters

Vancouver, BC, Canada

Website

www.nervgen.com